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 SUMMARY STATEMENT 
Mechanisms of renal fibrosis causing kidney failure are incompletely understood.  Here, Piret et al. 
establish a mouse model for renal fibrosis, which represents human disease due to uromodulin 
mutations, revealing roles for endoplasmic reticulum stress and unfolded protein responses. 
 
 
ABSTRACT 
Renal fibrosis is a common feature of renal failure resulting from multiple aetiologies, including 
diabetic nephropathy, hypertension and inherited renal disorders.  However, the mechanisms of renal 
fibrosis are incompletely understood and we therefore explored these by establishing a mouse model 
for a renal tubular disorder, referred to as autosomal dominant tubulointerstitial kidney disease 
(ADTKD) due to missense uromodulin (UMOD) mutations (ADTKD-UMOD). ADTKD-UMOD, 
which is associated with retention of mutant uromodulin in the endoplasmic reticulum (ER) of renal 
thick ascending limb cells, is characterized by hyperuricemia, interstitial fibrosis, inflammation, and 
renal failure, and we used targeted homologous recombination to generate a knock-in mouse model 
with an ADTKD-causing missense cysteine to arginine uromodulin mutation (C125R).  
Heterozygous and homozygous mutant mice developed reduced uric acid excretion, renal fibrosis, 
immune cell infiltration and progressive renal failure, with decreased maturation and excretion of 
uromodulin, due to its retention in the ER. The ER stress marker, glucose regulated protein (GRP)78, 
was elevated in cells expressing mutant uromodulin in heterozygous and homozygous mutant mice, 
and this was accompanied by upregulation of two unfolded protein response pathways, both in vivo 
and ex vivo in primary thick ascending limb cells from homozygous mutant mice. However, this did 
not lead to an increase in apoptosis in vivo.  Thus, we have developed a novel mouse model for renal 
fibrosis, which will be a valuable resource to decipher the mechanisms linking uromodulin mutations 
with ER stress and renal fibrosis. 
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 INTRODUCTION 
Renal fibrosis is an integral factor in progression to end-stage renal failure (ESRF), regardless of the 
primary etiology, which may include diabetic nephropathy, hypertension or monogenic disorders 
(Eddy, 2014).  However, mechanisms of renal fibrosis are incompletely understood, and there are 
currently no therapies to reverse or slow down the progression of renal fibrosis (Eddy, 2014). 
Autosomal dominant tubulointerstitial kidney disease (ADTKD), a monogenic cause of renal fibrosis, 
is characterized by urine concentrating defects, interstitial nephropathy with immune cell infiltration 
and glomerulosclerosis, and progressive loss of renal function leading to ESRF (Eckardt et al., 
2015a). Mutations in four genes have been identified to cause ADTKD, with the most common being 
the UMOD gene, encoding uromodulin (Eckardt et al., 2015b; Hart et al., 2002; Turner et al., 2003), 
referred to as ADTKD-UMOD. ADTKD-UMOD was previously referred to as familial juvenile 
hyperuricemic nephropathy type 1 (FJHN1; OMIM #162000), medullary cystic kidney disease type 
2 (MCKD2; OMIM #603860) and glomerulocystic kidney disease (GCKD; OMIM #609886) 
(Eckardt et al., 2015b; Rampoldi et al., 2003).  In addition to the general clinical characteristics of 
ADTKD, patients with ADTKD-UMOD present with elevated serum urate concentrations due to low 
fractional excretion of uric acid (FEUA). 
 
Uromodulin, a 640 amino acid glycosylphosphatidylinositol (GPI) anchored protein, is only 
expressed in the thick ascending limb (TAL) of the loop of Henle (Rampoldi et al., 2011).  
Uromodulin is synthesized within the endoplasmic reticulum (ER), trafficked to the apical plasma 
membrane, cleaved into the tubule, and excreted in the urine, where it is the most abundant protein 
(Rampoldi et al., 2011).  Uromodulin likely contains: four epidermal growth factor (EGF)-like 
domains, of which the second and third are calcium-binding (cb) EGF domains; a cysteine-rich region 
which includes a domain of eight cysteines; and a zona pellucida (ZP) domain (Bokhove et al., 2016) 
(Fig. S1).  Several functions have been postulated for uromodulin, including: regulating sodium 
transport in the TAL by modulating the activity of the apical transporters NKCC2 and ROMK (Trudu 
et al., 2013); inhibiting renal stone formation; preventing bacterial colonization; and modulating 
immune responses (Bates et al., 2004; Darisipudi et al., 2012; Mattey and Naftalin, 1992; Mo et al., 
2004a; Mo et al., 2007; Mo et al., 2004b; Raffi et al., 2009; Raffi et al., 2005; Saemann et al., 2005a; 
Saemann et al., 2005b).   
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 Over 90% of the >55 reported ADTKD-UMOD mutations are missense, suggesting a dominant 
negative disease mechanism, and >60% cause loss or gain of a cysteine residue (Moskowitz et al., 
2013), implicating a role for protein misfolding in ADTKD-UMOD. Most mutations are clustered in 
the EGF domains and cysteine-rich region, which are likely involved in formation of most of the 24 
disulfide bridges in uromodulin (Rampoldi et al., 2011), and uromodulin missense mutations cause 
altered intracellular trafficking, with retention of immature, core-glycosylated uromodulin in the ER, 
resulting in reduced or absent expression at the plasma membrane with little or no secretion 
(Bernascone et al., 2006; Choi et al., 2005; Dahan et al., 2003; Jennings et al., 2007; Rampoldi et al., 
2003; Vylet'al et al., 2006; Williams et al., 2009).  However, the role of uromodulin mutations in 
causing renal interstitial fibrosis, glomerulosclerosis and immune cell infiltration is not fully 
understood. 
 
ER accumulation of mutant proteins can cause ER stress, which activates the unfolded protein 
response (UPR), that may be adaptive or apoptotic in different tissues (Tsang et al., 2010), and 
consists of three pathways: the activating transcription factor-6 (ATF6), inositol-requiring 
enzyme-1 (IRE1) and RNA-activated protein kinase-like ER kinase (PERK) pathways. These act to 
upregulate chaperones and ER-associated degradation (ERAD) components, and reduce global 
protein translation to decrease the ER protein load.  Under prolonged and unresolved ER stress, cells 
may also undergo apoptosis (Tsang et al., 2010).  The ER stress-induced chaperone glucose-regulated 
protein (GRP) 78 (or binding immunoglobulin protein, BiP) is upregulated in renal biopsies from 
patients harboring mutations in UMOD (Adam et al., 2012); however, mechanisms of ER stress and 
the UPR pathways have not been studied further in ADTKD. 
 
Two Umod mouse knock-out models have been developed, which have revealed roles for uromodulin 
in: defense against bladder and urinary tract bacterial infections (Bates et al., 2004; Mo et al., 2004b; 
Raffi et al., 2009; Raffi et al., 2005); prevention of stone formation (Liu et al., 2010; Mo et al., 2004a; 
Mo et al., 2007); and water impermeability and solute handling in the TAL (Bachmann et al., 2005; 
Mutig et al., 2011; Renigunta et al., 2011; Wolf et al., 2013).  However, Umod knock-out mice up to 
3 years of age do not develop any of the histological features or renal failure characteristic of ADTKD 
(Raffi et al., 2006).  A transgenic mouse model carrying a human UMOD transgene containing the 
ADTKD-UMOD-causing mutation Cys148Trp (C148W) in addition to the two mouse Umod alleles, 
was not reported to have renal impairment or abnormal renal histology (Takiue et al., 2008a; Takiue 
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 et al., 2008b) (Table S1).  However, a second transgenic mouse expressing mouse Umod with the 
C148W mutation developed several features of ADTKD-UMOD, including mild renal failure, urinary 
concentrating defects and interstitial inflammation and fibrosis, but decreased uric acid excretion was 
not reported (Bernascone et al., 2010) (Table S1).  Thus, two similar transgenic models demonstrated 
two different phenotypes, and since in both models uromodulin was overexpressed compared to non-
transgenic mice, these models require cautious interpretation.  An N-ethyl-N-nitrosourea (ENU)-
generated uromodulin mutant (Ala227Thr; A227T) mouse has been described to develop azotemia, 
impaired urine concentrating ability, and reduced excretion of uric acid, but not renal fibrosis (Kemter 
et al., 2009), whilst a second ENU mutant, Cys93Phe (C93F), developed renal failure, urinary 
concentrating defects, interstitial fibrosis, inflammation and tubular defects (Kemter et al., 2013) 
(Table S1).  However, neither A227T or C93F are known disease-causing mutations in man. 
 
In order to study mechanisms of renal fibrosis, ADTKD-UMOD and ER stress due to uromodulin 
mutations relevant to ADTKD-UMOD in man, we generated a targeted mouse knock-in model by 
homologous recombination in mouse embryonic stem (ES) cells, to produce mice carrying a known 
disease-causing mutation, Cys125Arg (C125R), within the mouse Umod gene. Cysteine 125 (C125) 
is located within the cbEGF3 domain of uromodulin, and mutation of this residue is likely disrupts 
formation of the Ca2+ binding pocket which is formed by a set pattern of disulfide bonding within 
this domain (Turner et al., 2003) (Fig. S1).  C125 in mouse uromodulin is the equivalent of C126 in 
human uromodulin, and mutation of this residue to an arginine (C126R) has been reported to cause 
ADTKD-UMOD in man (Lhotta et al., 1998; Turner et al., 2003).  Furthermore, C126R uromodulin 
is retained in the ER of transfected cells (Williams et al., 2009), which is typical of several uromodulin 
mutations that have been characterised in vitro (Bernascone et al., 2006; Choi et al., 2005; Jennings 
et al., 2007; Rampoldi et al., 2003; Vylet'al et al., 2006; Williams et al., 2009).  This mutation was 
therefore selected as being representative of the majority of disease-causing uromodulin mutations.   
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  RESULTS 
Introduction of C125R mutation into the mouse germline 
A targeting vector containing 7.6kb of the mouse Umod gene, with the C125R mutation in exon 3, a 
thymidine kinase (TK) cassette at the 5’ end, and a neomycin resistance (NeoR) cassette in intron 2, 
was used to introduce the C125R mutation into the mouse genome by homologous recombination in 
ES cells (Fig. S1).  Of 272 ES cell clones which were selection resistant, 5 clones, termed B6, C2, 
D11, E10 and H10 were shown to have undergone homologous recombination at the 5' and 3' ends 
of the targeting construct by PCR/restriction assay (data not shown) and Southern blot analysis (Fig. 
1A).  Blastocyst injection of clone C2 resulted in the birth of chimeras with a high degree of 
chimerism (>~90%).  Male chimeras were bred with C57Bl/6J females and the mutation was shown 
to enter the germline by genotyping of mice using PCR and BsoBI restriction digest (Fig. 1B).  
Germline mutant mice were bred with -actin-Cre mice to excise the NeoR cassette.  Heterozygous 
(Umod+/125R) and homozygous (Umod125R/125R) mutant mice were viable and fertile with appearances 
and body weights (Table 1) similar to wild-type (Umod+/+) mice.  
 
Plasma biochemistry in 8 week and 6 month old Umod+/+, Umod+/125R and Umod125R/125R mice 
Male (p<0.001) and female (p<0.01) Umod125R/125R mice had plasma urea levels ~2-fold greater than 
those of Umod+/+ and Umod+/125R littermates at 8 weeks of age (Table 1).  By 6 months of age, plasma 
urea levels were increased ~1.5-fold and ~2.5-fold in Umod+/125R (male p<0.0001 and female p<0.01) 
and Umod125R/125R (male p<0.0001; female p<0.0001) mice, respectively, compared to Umod+/+ 
littermates (Table 1).  Plasma urea increased between 8 week and 6 month old Umod+/125R mice by 
~1.8-fold (p<0.0001) in males and ~1.2-fold (p<0.05) in females, demonstrating progressive renal 
failure (Table 1).  Plasma creatinine was also significantly raised by ~1.5-fold and ~1.8-fold, in 6 
month old Umod+/125R (p<0.05) and Umod125R/125R (p<0.001) males, respectively, and by ~1.2-fold in 
Umod125R/125R females (p<0.05) compared to age and sex matched Umod+/+ littermates (Table 1). 
Male and female 6 month old Umod125R/125R mice also had significantly raised plasma corrected 
calcium concentrations (p<0.01) compared to Umod+/+ littermates, which in conjunction with a 
significantly raised plasma alkaline phosphatase (ALP) activity (males p<0.001; females p<0.01), is 
consistent with the likely onset of tertiary hyperparathyroidism (Table 1). However, this 
hypercalcemia in association with raised plasma ALP activity in the Umod125R/125R mice, which has 
also previously been reported in two ENU-induced mutant mouse models with A227T and C93F 
Umod mutations (Kemter et al., 2009;Kemter et al., 2013) (Table S1), has not been observed to occur 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
 in ADTKD-UMOD patients who develop renal failure.  A plausible explanation for this occurrence 
of hypercalcemia, likely due to tertiary hyperparathyroidism, in Umod mutant mice but not ADTKD-
UMOD patients, is that the earlier detection of renal failure and associated secondary 
hyperparathyroidism, with appropriate treatment using vitamin D analogues, phosphate binders, and 
calcimimetics, will prevent the progression to tertiary hyperparathyroidism in patients.  Plasma uric 
acid levels were not increased in Umod+/125R or Umod125R/125R mice at 8 weeks or 6 months, likely 
due to expression of the hepatic enzyme uricase in mice (Wu et al., 1992).  Plasma sodium and 
potassium concentrations were similar in mutant and wild-type mice (data not shown). 
 
Urine biochemistry in 8 week and 6 month old Umod+/+, Umod+/125R and Umod125R/125R mice 
Male and female Umod125R/125R mice excreted ~2–4-fold increased volumes of urine (corrected for 
body weight) (p<0.0001), and this urine was more dilute with ~2–4-fold decreased urine osmolality 
(8 week old males and 6 month old males and females p<0.0001; 8 week old females p<0.05) 
compared to Umod+/+ littermates  (Table 2).  In addition, male Umod+/125R mice aged 8 weeks (p<0.05) 
and male and female Umod+/125R mice aged 6 months (p<0.05) had reduced urine osmolality, and 6 
month old male Umod+/125R mice also excreted 1.5 times more urine (p<0.05) compared to Umod+/+ 
littermates (Table 3).  In 6 month old Umod125R/125R males and females (p<0.01), and Umod+/125R 
males (p<0.05), this large excretion of dilute urine caused plasma osmolality to rise, and in other 
mutant mice, plasma osmolalities were inappropriately normal (Table 1).  Thus, Umod+/125R and 
Umod125R/125R mice have a urine-concentrating defect, which is similar to that reported in ADTKD-
UMOD patients (Rampoldi et al., 2003; Scolari et al., 2004). 
 
Twenty-four hour uric acid excretion was decreased in 6 month old mice by up to ~2.4-fold in 
Umod+/125R mice (males p<0.005; females p<0.05), and up to ~4.8-fold in Umod125R/125R mice (males 
p<0.005; females p<0.0001) compared to Umod+/+ littermates (Table 2).  In 8 week old Umod125R/125R 
males, 24 hour uric acid excretion was also decreased by ~1.6-fold compared to Umod+/+ male 
littermates (p<0.005) (Table 2).  This was not due to the dilute urine produced by these mice, since 
the 24 hour excretion takes urine volume into account.  In 6 month old mice, Umod+/125R and 
Umod125R/125R male and female mice had a significantly (p<0.05 to p<0.005) reduced FEUA, 
compared to Umod+/+ littermates (Table 2).  This specific reduction in uric acid excretion in 
Umod+/125R and Umod125R/125R mice is analogous to the human ADTKD-UMOD phenotype, in which 
>90% of patients have a decreased FEUA (Williams et al., 2009).   
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Urinary calcium excretion was elevated by ~1.6-fold (p<0.05) and ~1.8-fold (p<0.005) in 8 week old 
female Umod+/125R and Umod125R/125R mice, respectively, and elevated by ~1.5-fold in Umod+/125R 
(p<0.005) and Umod125R/125R (p<0.05) 6 month old males, and ~1.6-fold (p<0.005) and ~1.8-fold 
(p<0.0001) in Umod+/125R and Umod125R/125R 6 month old females, respectively, when compared to 
Umod+/+ littermates (Table 2).  This hypercalciuria of Umod mutant mice, which has not been 
described in human ADTKD-UMOD patients, was associated with urinary acidification. Thus, 
urinary pH was significantly reduced in 8 week old Umod125R/125R mice, corresponding to ~1.5-fold 
(p<0.005) and ~2.5-fold (p<0.0001) increases in urinary H+ ion concentrations in males and females, 
respectively, compared to Umod+/+ littermates (Table 2).  Six month old Umod+/125R and Umod125R/125R 
mice also had a decreased urinary pH corresponding to up to ~5.3-fold (p<0.0001) and ~7-fold 
(p<0.005) increases in urinary H+ ion concentrations in males and females, respectively, compared to 
Umod+/+ littermates (Table 2).  This urinary acidification helps to prevent renal stone formation, and 
is a likely renal response to hypercalciuria (Renkema et al., 2009). 
 
Uromodulin maturation, excretion and trafficking in 8 week and 6 month old Umod+/125R and 
Umod125R/125R mice 
The C126R uromodulin mutation results in defective maturation, trafficking and secretion of 
uromodulin in vitro (Williams et al., 2009), and we therefore carried out Western blot analysis of 
kidney lysates and urine, and immunohistochemistry to study this in Umod mutant mice.  Kidney 
lysates from Umod+/+ mice showed the presence of uromodulin at ~100kDa as previously described 
(Bates et al., 2004), corresponding to mature, fully glycosylated uromodulin (Fig. 1C).  Kidney 
lysates from Umod+/125R mice at 8 weeks and 6 months of age had mature uromodulin and a lower 
molecular weight form of uromodulin, likely the ER-resident precursor which has core glycosylations 
only (Williams et al., 2009).  Kidney lysates from Umod125R/125R mice almost entirely lacked mature 
uromodulin, with a predominance of the precursor form of uromodulin.  Higher molecular weight 
bands were detected in kidney lysates from Umod+/125R and Umod125R/125R mice at 8 weeks and 6 
months, at approximately double the molecular weight of the precursor uromodulin; these may 
represent dimers of precursor uromodulin, which would likely be retained in the ER (Fig. 1C).  
 
Urinary uromodulin excretion was studied by Western blot and densitometric analysis (Fig. 1D).  
Uromodulin is the most abundant protein in the urine (Scolari et al., 2015); therefore to enable 
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 accurate Western blot analysis, samples from Umod+/+ and Umod+/125R mice were diluted 20-fold, but 
samples from Umod125R/125R mice were not diluted.  Sample loading was standardised for equal 
creatinine concentration, to correct for the more dilute urine in mutant mice.  Eight week old male 
and female Umod+/125R mice had a significantly reduced uromodulin excretion of 66.8±3.3% and 
69.1±4.5%, respectively, compared to Umod+/+ littermates (p<0.001) (Fig. 1D).  This preceded the 
onset of renal failure, as measured by an increase in plasma urea (Table 1).  Furthermore, this decrease 
in uromodulin excretion was progressive, since both Umod+/125R and Umod125R/125R mice at 6 months 
old excreted significantly less uromodulin than mice of the same sex and genotype aged 8 weeks old 
(Fig. 1D).  For example, uromodulin excretion in male Umod+/125R mice decreased from 49.8±10.3% 
at 8 weeks old to 15.7±2.9% at 6 months old when compared to Umod+/+ littermates (p<0.00001).  
All of the excreted uromodulin was the mature form of uromodulin at ~100kDa, with no detectable 
excretion of the precursor form of uromodulin. 
 
Immunohistochemical analysis of uromodulin expression in 8 week and 6 month old Umod+/+, 
Umod+/125R and Umod125R/125R kidneys showed the expected uromodulin trafficking defect in mutant 
kidneys (Fig. 1E).  In Umod+/+ kidneys, uromodulin expression had a predominantly apical pattern, 
with low levels of diffuse intracellular uromodulin also present as previously described (Kemter et 
al., 2009), and uromodulin was observed in the tubular lumen.  In Umod+/125R and Umod125R/125R 
kidneys, apical expression was decreased, and dense intracellular expression was observed, such that 
in Umod+/125R kidneys, uromodulin was partly apical and partly intracellular, and in Umod125R/125R 
kidneys, uromodulin was almost exclusively located in dense intracellular deposits.  Dual-labeling 
for uromodulin and the ER marker calnexin showed that the intracellular uromodulin in Umod+/125R 
and Umod125R/125R kidneys was co-localized with the ER (Fig. 1F), as previously demonstrated both 
in vitro (Williams et al., 2009) and in ADTKD-UMOD patients (Bernascone et al., 2010), and 
consistent with presence of the lower weight precursor detected by Western blotting (Fig. 1C).  In 
Umod+/125R mouse kidneys, uromodulin co-localized with calnexin and was present at the apical 
membrane. 
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Renal fibrosis and immune cell infiltration in 8 week and 6 month old Umod+/125R and Umod125R/125R 
mice 
Masson’s trichrome staining to study renal damage and fibrosis, of kidney sections from 8 week and 
6 month old mice, revealed that at 8 weeks, kidneys of Umod+/125R mice did not have any 
abnormalities, but that kidneys of Umod125R/125R mice had thickened basement membranes and some 
intracellular fibrous deposits, similar to those reported in a renal biopsy from a patient with a UMOD 
mutation (Nasr et al., 2008).  Glomeruli appeared normal in both Umod+/125R and Umod125R/125R mouse 
kidneys at 8 weeks of age (Fig. 2A).  At 6 months of age, Umod+/125R mouse kidneys had mild 
interstitial fibrosis, and Umod125R/125R mouse kidneys had large areas of fibrosis, with some renal 
tubules appearing to become detached from the basement membrane.  Furthermore, some glomeruli 
in Umod125R/125R mouse kidneys also had increased fibrotic material, consistent with 
glomerulosclerosis (Fig. 2A).  No cysts were observed in Umod+/125R or Umod125R/125R mouse kidneys 
at 8 weeks or 6 months of age. 
 
During analysis of uromodulin-labeled and trichrome stained kidney sections, interstitial cell 
infiltrates were noted.  To determine the nature of these infiltrates, kidney sections were labeled for 
T-cell (CD3) and macrophage (F4/80) markers. Umod+/125R mouse kidneys at 8 weeks of age had no 
detectable immune cell infiltration; however, Umod125R/125R mouse kidneys showed small areas of 
interstitial infiltrates, consisting of T-cells and macrophages (Fig. 2B,C).  At 6 months of age, 
Umod+/125R mouse kidneys showed small areas of interstitial T-cells and macrophages, but 
Umod125R/125R mouse kidneys had multiple, large areas of interstitial infiltrates, consisting of both T-
cells and macrophages (Fig. 2B,C).  These infiltrates occurred mainly in the medullary region, and 
often in close proximity to TAL cells expressing mutant uromodulin. 
 
Upregulation of ER stress and unfolded protein response (UPR) pathways in mutant TALs  
Accumulation of mutant proteins in the ER may cause ER stress, triggering an adaptive pathway 
called the unfolded protein response (UPR).  Members of the chaperone family of GRPs, and in 
particular GRP78, are upregulated by the UPR in response to ER stress.  We therefore used 
immunohistochemistry of serial kidney sections to investigate GRP78 expression in TAL cells 
expressing mutant uromodulin.  In Umod+/+ kidneys, GRP78 was expressed at a very low level in 
non-TAL tubular epithelial cells, and at a slightly elevated level in TAL tubular cells (Fig. 3A,B), a 
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 finding that was confirmed in kidneys from an unrelated mouse line (data not shown).  However, in 
kidneys from both 8 week and 6 month old Umod+/125R and Umod125R/125R mice, GRP78 expression 
was upregulated specifically in TAL cells expressing mutant uromodulin, and not in other tubular 
segments (Fig. 3A,B).   
 
We sought to determine which of the three UPR pathways may be active in TAL cells expressing 
mutant uromodulin, by immunohistochemistry to detect expression of a member of each of the three 
pathway, which are: ATF6 (ATF6 pathway), spliced (active) XBP1 (XBP1S; IRE1 pathway) or 
ATF4 (PERK pathway).  None of the three pathways were upregulated in TAL cells in Umod+/+ mice 
when compared to non-TAL cells (Fig. 4A,B).  No activation of the ATF6 pathway was detected in 
Umod+/125R or Umod125R/125R mice at either 8 weeks or 6 months of age, as there was no increase in 
nuclear ATF6 expression in TAL cells (Fig. 4A,B).  By contrast, both XBP1S and ATF4 were 
upregulated in TAL cells of Umod+/125R and Umod125R/125R mice compared to Umod+/+ littermates at 
both 8 weeks and 6 months of age (Fig. 4A,B), demonstrating upregulation of the IRE1 and PERK 
pathways, respectively, in response to retention of mutant uromodulin in the ER. 
 
In order to quantify the upregulation of these ER stress and UPR pathways, we microdissected TALs 
from Umod+/+ and Umod125R/125R mice.  qRT-PCR analysis for nephron segment-specific genes was 
undertaken to demonstrate the purity of the obtained TALs (data not shown), followed by qRT-PCR 
and Western blot analyses for UPR components.  qRT-PCR analysis showed that Xbp1S and Atf4 
were significantly upregulated by ~1.9-fold (p<0.01) and ~1.6-fold (p<0.001), respectively, in 
Umod125R/125R TALs compared to Umod+/+ TALs, but that Grp78 and Atf6 expression levels were 
not significantly different (Fig. 5A).  However, Western blot analysis showed that GRP78 protein 
was significantly upregulated by ~4.2-fold (p<0.001) in Umod125R/125R TALs compared to Umod+/+ 
TALs, consistent with regulation of GRP78 expression at the translational level (Gulow et al., 2002) 
(Fig. 5B,C).  Interestingly, ATF6 was significantly downregulated by ~1.8-fold (p<0.05) in 
Umod125R/125R TALs compared to Umod+/+ TALs (Fig. 5B,C).  XBP1S and ATF4 were significantly 
upregulated by ~13.6-fold (p<0.001) and ~4.5-fold (p<0.01), respectively in Umod125R/125R TALs 
(Fig. 5B,C), confirming the results obtained by immunohistochemical analysis. 
 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
 Upregulation of the PERK pathway via ATF4 is associated with suppression of general protein 
translation but induction of expression of specific UPR target genes, such as CCAAT/enhancer-
binding protein homologous protein (CHOP) (Hetz, 2012).  qRT-PCR analysis of isolated TALs 
showed that Umod mRNA was downregulated by ~6.6-fold (p<0.001) in Umod125R/125R TALs 
compared to Umod+/+ TALs (Fig. 5A).  Chop mRNA was upregulated by ~2.2-fold (p<0.001) in 
Umod125R/125R TALs compared to Umod+/+ TALs (Fig. 6A), and immunohistochemical analysis of 
serial kidney sections confirmed that CHOP protein was upregulated in TAL cells in Umod+/125R and 
Umod125R/125R mice compared to Umod+/+ littermates at both 8 weeks and 6 months of age, as shown 
by accumulation of CHOP in the nuclei of TAL cells (Fig. 6A,B).  Increased CHOP expression may 
lead to apoptosis (Hetz, 2012); however, analysis of kidney sections using terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay and co-staining for uromodulin showed that as 
in Umod+/+ littermates, there were no TUNEL-positive TAL cells in Umod+/125R and Umod125R/125R 
mouse kidneys at either 8 weeks or 6 months of age (Fig. 6A,B). However, occasional TUNEL-
positive cells were detected in other segments, demonstrating that the assay was functional.  Thus, 
mechanisms other than apoptosis are likely responsible for tubular damage in Umod+/125R and 
Umod125R/125R mice.  
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 DISCUSSION 
We have generated a mouse model with an ADTKD-disease causing UMOD mutation, that displays: 
defective uric acid excretion; urinary concentrating defects; renal failure; defective uromodulin 
trafficking, maturation and secretion; renal fibrosis, interstitial immune cell infiltration, and ER stress 
with upregulation of the UPR in the TAL.  This model is representative of ADTKD-UMOD patients 
who develop hyperuricemia, low FEUA and gout, chronic renal failure, tubulointerstitial 
nephropathy, glomerulosclerosis and lymphocytic infiltration (Lhotta et al., 1998; Turner et al., 
2003).  Thus, this mouse provides an in vivo model to study mechanisms of renal fibrosis and ER 
stress. 
 
A major feature of ADTKD-UMOD in man is hyperuricemia, which was not present in Umod mutant 
mice.  This is not surprising, as mice express the hepatic enzyme uricase (urate oxidase), which 
catalyses low solubility uric acid to the high solubility allantoin; uricase has been evolutionarily 
silenced in humans and other primates (Wu et al., 1992).  However, Umod+/125R and Umod125R/125R 
mice, similar to ADTKD-UMOD patients, still demonstrated significant decreases in both FEUA and 
24-hour uric acid excretion.  Interestingly, in female Umod125R/125R mice, this decreased uric acid 
excretion was detected after the onset of renal failure, as measured by a significantly increased plasma 
urea, since 8 week old Umod125R/125R females had an elevated plasma urea, but a similar uric acid 
excretion compared to Umod+/+ females.  The role of plasma uric acid levels in the pathogenesis of 
ADTKD-UMOD has been the subject of much debate, particularly whether drugs which lower plasma 
uric acid may slow the progression of ADTKD-UMOD in patients (Bleyer and Hart, 2003; Fairbanks 
et al., 2002; Fairbanks et al., 2004; Puig et al., 2006; Puig and Torres, 2003; Puig and Torres, 2004).  
Our model demonstrates that hyperuricemia is a secondary consequence of the other phenotypes of 
ADTKD-UMOD (e.g. decreased uric acid excretion, renal failure, and kidney histopathology), and is 
not required to cause the renal pathophysiology, since our model develops these other phenotypes 
without hyperuricemia.  However, hyperuricemia may help to propagate or enhance the disease 
progression in humans, and this hypothesis could be tested in our model by using uricase inhibitors. 
 
The mechanism of decreased uric acid excretion is not fully understood, but may be a consequence 
of the urine concentrating defect. In the normal TAL, the water impermeability is likely due to the 
presence of uromodulin in a gel-like structure at the apical plasma membrane, which is permeable to 
ions but not to water (Mattey and Naftalin, 1992).  In Umod+/125R and Umod125R/125R mice, retention 
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 of the mutant uromodulin protein in the ER of the TAL cells would decrease the amount of 
uromodulin at the apical plasma membrane, and may compromise this water impermeability.  This 
may lead to a reduction in the normally high osmolality of the medullary interstitium, thus inhibiting 
water reabsorption in the collecting duct (CD), and resulting in a more dilute urine (Devuyst et al., 
2005).  The previously reported Umod-/- knock-out mice also have a urine concentrating defect 
(Bachmann et al., 2005).  This defect in urine concentration due to alterations of TAL characteristics, 
may be analogous to patients treated with loop diuretics, such as those with hypertension, who also 
develop secondary hyperuricemia (Ramsay et al., 1994).  Loop diuretics (e.g. furosemide) specifically 
inhibit the TAL Na+:K+:2Cl- (NKCC2) transporter, decreasing water reabsorption with a consequent 
increase in urine volume (Gamba and Friedman, 2009).  During loop diuretic treatment, the resulting 
decrease in extracellular fluid (ECF) volume causes increased sodium reabsorption by the proximal 
convoluted tubule (PCT), which likely drives increased uric acid reabsorption, hence causing the 
hyperuricemia which is often associated with these drugs (Weinman et al., 1975).  A possible 
compensatory mechanism for excess water loss has been described in Umod-/- knock-out mice by 
upregulation of several critical TAL ion transporters, including the target of loop diuretics, NKCC2, 
which is usually activated by uromodulin (Bachmann et al., 2005).  Thus, similar mechanisms may 
be responsible for hyperuricemia in loop diuretic-treated hypertensive patients and ADTKD-UMOD 
patients; this requires further investigation in Umod+/125R and Umod125R/125R mice. 
 
The urine concentrating defect described in Umod-/- knock-out mice (Bachmann et al., 2005) and 
Umod+/125R and Umod125R/125R mice in this study, is likely due to the absence of uromodulin at the 
apical plasma membrane of the TAL.  However, Umod-/- knock-out mice do not develop any 
histological characteristics of ADTKD-UMOD, or renal failure (Raffi et al., 2006).  Thus, mutant 
uromodulin protein must be present to cause the renal pathology associated with ADTKD-UMOD, 
and we have shown that histopathologic changes characteristic of human ADTKD-UMOD patients, 
such as interstitial fibrosis and immune cell infiltration, are present in our Umod+/125R and 
Umod125R/125R knock-in mice.  Uromodulin is the most abundant protein in the urine, and is expressed 
only by the TAL (Scolari et al., 2015), indicating a high rate of uromodulin expression in TAL cells.  
Thus, even though cells possess mechanisms to degrade misfolded proteins, such as ERAD, the high 
expression rate of mutant uromodulin over time may overwhelm such mechanisms.  Uromodulin can 
also stimulate the innate and adaptive immune systems (Saemann et al., 2005b; Su et al., 1997).  Thus, 
it has been postulated kidney damage may compromise its integrity and allow uromodulin to be 
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 exposed to the immune system, which may cause antibody production (Saemann et al., 2005b), as 
well as inflammation and/or immune cell infiltration, which can result in fibrosis of the kidney (Eddy, 
2014). 
 
Umod+/125R and Umod125R/125R mice have several phenotypic characteristics that are similar to those 
reported for the C147W uromodulin transgenic (TgUmodC147W) mouse model, including renal failure, 
urinary concentrating defects, fibrosis, immune cell infiltration and intracellular uromodulin 
retention.  However, Umod+/125R and Umod125R/125R mice had a selective defect in renal uric acid 
handing that was not studied in TgUmodC147W transgenic mice (Bernascone et al., 2010), whereas 
TgUmodC147W mice had renal cysts, which were not detected in Umod+/125R or Umod125R/125R mice 
(Table S1).  The reason for these differences between Umod125R mice and TgUmodC147W mice remains 
to be elucidated, but there are several possible explanations.  First, these differences may involve 
strain-specific factors, as the TgUmodC147W mice were generated on a FVB background, whilst the 
Umod125R mice were on a C57BL/6 background.  Second, the TgUmodC147W mice are a transgenic 
model that express Umod at higher levels than wild-type mice without the transgene, whereas in 
Umod125R mice, the mutant Umod directly replaces the wild-type allele.  Third, TgUmodC147W mice 
express mutant uromodulin with a different mutation compared to Umod125R mice.  Patients with 
different mutations have marked variations in some phenotypic features such as rate of progression 
to ESRF (Moskowitz et al., 2013); however, this does not seem to be true of hyperuricemia, which is 
present in >90% of patients.  The presence or absence of cysts is the most variable phenotype 
associated with ADTKD-UMOD in man and may only be found in <15% of patients (Williams et al., 
2009).  Indeed, different members of the same family may have variable cyst formation (Rampoldi 
et al., 2003; Vylet'al et al., 2006); this variation may be due to other genetic differences or 
environmental factors rather than different UMOD mutations.  Cysts have not been reported in 
families with either the C126R or C148W mutations (Lhotta et al., 1998; Rampoldi et al., 2003), and 
the basis for this variation in cyst formation between different families, family members, and mouse 
models requires further investigation.  Two ENU-mutagenized mouse models, carrying A227T or 
C93F uromodulin mutations on the same backgrounds, have recently been described to have differing 
rates of disease onset and progression, with C93F mutant mice having the more severe phenotype 
(Kemter et al., 2013).  The ENU mutant mice both displayed decreased uric acid excretion that was 
present in Umod125R mice but absent in TgUmodC147W mice, tubulocystic changes that were present in 
TgUmodC147W mice but absent in Umod125R mice, and glomerulocystic changes that were absent in both 
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 TgUmodC147W and Umod125R mice (Bernascone et al., 2010; Kemter et al., 2013) (Table S1).  These 
differences between the germline Umod125R, transgenic TgUmodC147W and ENU A227T and C93F mice 
with different mutations highlight the advantages of having multiple mouse models that provide the 
opportunity of elucidating further the relationships between protein, uromodulin mutation, genetic 
modifiers, phenotype and mechanism in ADTKD-UMOD. 
 
Our results provide mechanistic insights by showing that ER stress is present in TAL cells expressing 
mutant uromodulin, and that two of the three UPR pathways (PERK and IRE1) are active, leading to 
upregulation of CHOP.  However, this did not lead to apoptosis of TAL cells, demonstrating that 
other mechanisms may be responsible for TAL damage, and consequent fibrosis and immune cell 
infiltration in this model. CHOP is a transcription factor typically thought to upregulate pro-apoptotic 
pathways; however, it may also be protective under certain conditions in different cell types.  For 
example, mice with autosomal dominant retinitis pigmentosa due to ER-retention of mutant 
rhodopsin have retinal damage that is associated with UPR and CHOP upregulation; however, 
deletion of CHOP led to increased retinal damage in these mice, suggesting a protective role for 
CHOP (Nashine et al., 2013). Several studies have implicated ER stress, leading to CHOP expression 
and apoptosis, in models of renal disease.  However, these studies have primarily investigated the 
renal response to toxins (e.g. high glucose in diabetic nephropathy or high albumin levels to mimic 
proteinuria), drugs (e.g. acetaminophen), or acute renal injury (e.g. using unilateral ureteric 
obstruction); or have focussed on glomerular injury (Dickhout and Krepinsky, 2009).  Relatively little 
work has been carried out to understand the role of chronic ER stress in renal tubule cells 
endogenously expressing an ER-retained mutant protein, and our mouse model for ADTKD-UMOD 
will be an important resource for further studies in this area. Active XBP1 protein was also 
upregulated in TAL cells in Umod125R mice, demonstrating upregulation of the IRE1 pathway, and 
this may also be an adaptive or apoptotic response to ER stress (Ghosh et al., 2014).  During prolonged 
ER stress, PERK signaling is maintained whilst IRE1 signaling is attenuated, which may lead to a 
switch from adaptive to apoptotic signalling (Lin et al., 2007).  Consistent with this hypothesis, 
prolonged IRE1 signalling enhanced cell proliferation and prevented apoptosis when human 
embryonic kidney (HEK)293 cells were exposed to the UPR inducers tunicamycin and thapsigargin 
(Lin et al., 2007; Lin et al., 2009). In Umod125R mice, both the PERK and IRE1 pathways appeared 
to be active even at 6 months of age, and the presence of both of these pathways may explain the 
absence of the apoptotic response in TAL cells in these mice.  Studies of the transgenic TgUmodC147W 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
 mice also showed an absence of apoptosis by a lack of active caspase-3 staining, thus apoptosis does 
not appear to play a significant role in tubule damage in ADTKD-UMOD (Bernascone et al., 2010). 
 
In conclusion, we have generated a mouse model for a monogenic cause of renal fibrosis carrying an 
ADTKD-UMOD disease-causing mutation, C125R, in the endogenous mouse Umod gene. 
Umod+/125R and Umod125R/125R mice demonstrate several of the phenotypes of human ADTKD-
UMOD patients, including progressive renal failure, urine concentrating defects, decreased uric acid 
and uromodulin excretion, retention of uromodulin in the ER, and pathologic changes in the kidney 
such as fibrosis, immune cell infiltration and ER stress.  The PERK and IRE1 UPR pathways were 
found to be specifically upregulated in TAL cells of Umod+/125R and Umod125R/125R mice, which was 
associated with upregulation of CHOP; however this did not lead to apoptosis.  This novel knock-in 
mouse model will be a valuable resource to study the mechanisms of pathogenesis and progression 
of renal fibrosis, ESRF and ADTKD-UMOD and to test novel therapeutic agents for these diseases. 
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 MATERIALS AND METHODS 
Generation of knock-in targeting vector and mutant mice 
Exon 3 of mouse Umod was amplified by PCR and used to screen a mouse PAC library (MRC 
Geneservice, Cambridge, UK).  A PAC containing mouse Umod was then used as a template in a 
long-range PCR reaction to amplify a ~7.6kb product between the 5' upstream region and intron 5 of 
Umod.  Exon and intron-exon boundary sequences were verified by direct DNA sequencing as 
described (Nesbit et al., 2004).  After insertion into pGEM-T (Promega, Southamptom, UK), site-
directed mutagenesis (SDM) was performed to introduce the C125R mutation as described (Nesbit et 
al., 2004); during this procedure, a novel BsoBI restriction site was also generated.  SDM was also 
used to introduce a HindIII site into intron 2.  Following each round of SDM, the sequences of exons 
and intron-exon boundaries were verified by direct DNA sequencing.  A neomycin resistance (NeoR) 
cassette flanked by two LoxP sites, was excised from plasmid pmmneoflox8 and cloned into intron 2 
of Umod using XbaI and HindIII.  Plasmid pBSTK, containing a thymidine kinase (TK) cassette was 
mutagenized by SDM to introduce a SfiI restriction site, and the TK cassette was inserted into the 
targeting vector at the 5' end of the Umod gene using SfiI and SacII (Fig. S1).  The vector was 
linearized using SbfI, electroporated into the R1 embryonic stem (ES) cell line, and cells selected 
using 300µg/ml G418 (Geneticin, Gibco, Paisley, UK) and 0.2µM Gancyclovir (Calbiochem, 
Manchester, UK).  Cells in which homologous recombination had occurred at both 5’ and 3’ arms 
were identified by PCR/restriction digest and Southern blot analysis (Harding et al., 2009) as follows: 
5’ PCR: forward primer in the 5’ region outside the vector and reverse primer within the NeoR cassette 
generated a 2.8kb product only in recombined clones; 3’ PCR: forward primer within exon 3 and 
reverse primer within intron 5 (outside the vector) generated a 5.3kb fragment in all clones, which 
when digested with BsoBI generated an extra fragment in recombined clones; 5’ Southern blot: 
digestion with PflFI and a probe within the 5’ upstream region detected an ~11.6kb Umod wild-type 
fragment and an ~7.4kb Umod mutant fragment; 3’ Southern blot: digestion with SpeI and a probe 
corresponding to exon 6 of Umod detected an ~8.3kb Umod wild-type fragment and an ~9.6kb Umod 
mutant fragment (Fig. 1A). ES cells heterozygous for the mutation were injected into C57BL/6 
blastocysts at embryonic day 2.5, which were transferred into the uterus of pseudopregnant C57BL/6 
females.  Male chimeras were mated with C57BL/6 females and the offspring tested for germline 
transmission by extraction of DNA from ear biopsy material in DNA extraction buffer (50mM Tris 
pH8.5, 1mM EDTA, 0.5% Tween-20, with 50µg Proteinase K), followed by PCR and BsoBI 
digestion.  The NeoR cassette was excised between LoxP sites by mating with -actin-Cre mice, and 
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 the removal of the NeoR cassette was verified by PCR assay. Mice were backcrossed to the C57Bl/6J 
background strain and mice from backcross (BC)3-BC5 were used for studies in 6 month old mice, 
and from BC4-BC7 for studies in 8 week old mice.  Animals were maintained according to local 
welfare guidelines, and all procedures were carried out under UK Home Office personal and project 
license restrictions.  
 
Metabolic cage analysis 
Eight week and 6 month old Umod+/+, Umod+/125R and Umod125R/125R littermates were investigated in 
individual metabolic cages (Techniplast) for 24 hours with free access to food and water.  Body 
weight, water intake and urine output were measured and urine was collected under mineral oil.  Mice 
were euthanized by terminal anaesthesia, blood collected via the jugular vein, and plasma obtained 
by centrifugation at 800g for 10 minutes.  Plasma and urine biochemical analysis was performed on 
a Beckman Coulter AU680 semi-automated clinical biochemistry analyser as described (Piret et al., 
2012), and plasma calcium was corrected for albumin (Corr.Ca) using the formula: Corr.Ca = Ca 
(mmol/l)–((Alb(g/l)-30)x0.017) (Piret et al., 2012).  Osmolalities were measured using a Model 3320 
Osmometer (Advanced Instruments Inc., Norwood, MA, USA) and urinary pH was measured using 
a Microprocessor pH meter (Hanna Instruments, Leighton Buzzard, UK). 
 
Western blot analysis of whole kidney lysates and urine 
Uromodulin maturation and excretion in Umod+/+, Umod+/125R and Umod125R/125R mutant mice were 
studied by Western blot analysis of kidney lysates and urine samples. Kidneys were homogenised in 
-octylglucoside lysis buffer (20mM Tris-HCl pH8; 150mM NaCl; 60mM -octylglucoside 
(Bernascone et al., 2010)) with a protease inhibitor cocktail (Roche, Burgess Hill, UK).  Insoluble 
material was removed by centrifugation, total protein concentration of the soluble fraction determined 
using the micro BCA Protein Assay (Pierce, UK) (Bernascone et al., 2010; Williams et al., 2009), 
and lysates loaded at 20-50µg total protein per lane.  Urine samples were normalized to urinary 
creatinine such that for Umod+/+ and Umod+/125R samples, a urine volume corresponding to 0.5nmol 
creatinine was loaded, and for Umod125R/125R samples, a urine volume corresponding to 10nmol was 
loaded.  Western blotting and densitometric analysis were performed as previously described, using 
sheep anti-uromucoid antibody (Biodesign International, Saco, ME, USA), or rabbit anti-tubulin 
antibody (Abcam ab15246, 1:500), followed by horseradish peroxidase (HRP)-conjugated mouse 
anti-sheep (Sigma, Poole, UK) or HRP-conjugated goat anti-rabbit (BioRad, Watford, UK) 
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 antibodies, respectively (Williams et al., 2009).  To control for variances between blots of urinary 
uromodulin, at least two Umod+/+ samples were loaded on each gel, a standard “remove background” 
tool was used prior to quantification by densitometry, and mean densities of Umod+/+ bands were set 
to 100% for comparison with other bands on the same blot. 
 
Histological and immunohistochemical analysis 
Kidneys were dissected and fixed in 10% neutral buffered formalin for 24 hours, then dehydrated, 
paraffin embedded, and sectioned at 5µm thickness. Trichrome staining was carried out according to 
standard protocols.  For immunohistochemical labeling, sections were rehydrated, then subjected to 
antigen unmasking either by incubation in 20µg/ml proteinase K for 5 – 15 minutes, or by heat-
mediated antigen retrieval in either pH6, pH9 or pH10 buffers.  Sections were blocked in pre-immune 
serum, and probed with the following primary antibodies: sheep anti-uromucoid (Biodesign 
International, 1:500); rabbit anti-calnexin (Abcam ab22595, 1:50); rabbit anti-CD3 (Abcam ab16669, 
1:50); rat anti-F4/80 (Serotec clone A3-1, 1:50); rabbit anti-GRP78 (Abcam ab21685, 1:1000); rabbit 
anti-ATF4 (Abcam ab105383, 1:500); rabbit anti-ATF6 (Santa Cruz sc-22799, 1:50); goat anti-
XBP1 (spliced) (Abcam ab85546, 1:100); or rabbit anti-CHOP (Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) sc-575, 1:50).  Secondary detection was achieved by: HRP-conjugated donkey anti-
sheep antibody (Jackson ImmunoResearch, 1:500) visualised using the 3,3’-Diaminobenzidine 
(DAB) reaction kit (Vector Labs, Peterborough, UK) for uromodulin; the DAKO Envision+ System 
DAB kit for rabbit primary antibodies; the Santa Cruz ABC staining system for goat primary 
antibodies; or fluorescently conjugated donkey secondary antibodies (Jackson ImmunoResearch or 
Invitrogen) for dual-labeling.  TUNEL assay was performed using the ApopTag Fluorescein kit 
(Millipore, Herts, UK) according to manufacturer’s instructions.  DAB-stained slides were 
counterstained with hematoxylin, and fluorescently labeled slides were counterstained with 4',6-
diamidino-2-phenylindole (DAPI).  Slides were examined by light or UV microscopy using an 
Eclipse E400 microscope (Nikon, Japan), and images were captured using a DXM1200C digital 
camera, with an original magnification of 20x or 40x, and NIS-Elements BR2.30 software (both 
Nikon).  Immunohistochemistry was performed on 2 kidney sections from each of 4 mice per group. 
 
Isolation of mouse TALs, and qRT-PCR and Western blot analyses 
Mouse TALs were isolated following a previously described protocol (Glaudemans et al., 2014) with 
minor modifications.  Briefly, 2-3 month old male Umod+/+ and Umod125R/125R mice were sacrificed 
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 by cervical dislocation. Kidneys were removed, decapsulated and placed in ice-cold dissection 
solution (Hanks balanced salt solution with 15mM HEPES, 10mM D-glucose, 5mM glycine, 1mM 
L-alanine, adjusted to 325mOsm/kgH2O with mannitol and pH7.4 with NaOH).  Each kidney was cut 
into 2 equal parts by a midsagittal section and then into thin transverse slices that were further cut 
into radial cortico-medullary stripes. Kidney pieces were digested for 30 minutes in dissection 
solution supplemented with 245U/mL type 2 collagenase (Worthington Biochemical Corp, 
Lakewood, USA) and 96µg/mL soybean trypsin inhibitor (Sigma-Aldrich) at 37°C on a shaker. The 
supernatant containing small kidney fragments and isolated tubules was sieved through 250µm and 
50µm filters (Sefar AG, Heiden, Switzerland) and tubules retained on the 50µm filter were collected 
in 37°C dissection solution supplemented with 1% BSA (Sigma-Aldrich) and 96µg/mL soybean 
trypsin inhibitor (Sigma-Aldrich). Remaining undigested kidney fragments were digested for 10 
minutes in fresh collagenase solution. TALs were manually selected under a light microscope using 
a glass pipet connected to a micromanipulator (Narishige International, London, UK). Total RNA 
was extracted from microdissected TALs using RNAqueous® Total RNA Isolation Kit (Invitrogen, 
Massachusetts, USA), following the manufacturer’s protocol and DNAseI treatment performed. The 
reverse transcriptase (RT) reaction was performed using 1µg of RNA and the iScriptTM cDNA 
Synthesis Kit (Bio-Rad).  Changes in mRNA levels of target genes were determined by relative qRT-
PCR with a CFX96TM Real-Time PCR Detection System (Bio-Rad) using iQTM SYBR Green 
Supermix (Bio-Rad) detection of single PCR product accumulation in duplicate. Specific primers 
were designed using Primer3. PCR conditions were 95°C for 3min followed by 40 cycles of 15sec at 
95°C, 30sec at 60°C. PCR products were sequenced using the BigDye terminator kit (Perkin Elmer 
Applied Biosystems, Massachusetts, USA), purified using the multiScreen SEQ384 Filter Plate 
(Millipore) and Sephadex G-50 DNA Grade Fine (Amersham Biosciences, New Jersey, USA), and 
analysed on an ABI3100 capillary sequencer (Perkin Elmer Applied Biosystems). The efficiency of 
each set of primers was determined by dilution curves. Glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh) was used routinely as a reference gene. Relative changes in target gene/Gapdh mRNA ratio 
were determined by the formula: 2ΔΔct.  For Western blot analysis, 50-70 TALs were pooled and 
directly transferred in 4x Laemmli sample buffer (Bio-Rad) supplemented with protease inhibitors 
(Roche, Basel, Switzerland) and 60mg/mL dithiothreitol (AppliChem) and boiled at 95°C for 5min.  
Western blotting and densitometric analysis were performed using antibodies against ATF4, ATF6, 
GRP78 and spliced XBP1, as above. 
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 Statistical analysis 
Statistical analyses were performed using Student's unpaired t-test or the Mann-Whitney U test, 
where appropriate. 
 
Study approval 
All animal studies were approved by the University of Oxford Ethical Review Committee and were 
licensed under the Animals (Scientific Procedures) Act 1986, issued by the United Kingdom 
Government Home Office Department. 
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 Figures 
 
 
 
Fig. 1. Uromodulin maturation, excretion and trafficking. (A) Homologous recombination in ES 
cell clones assessed by Southern blot analysis: DNA from 5 clones (B6, C2, D11, E10, H10) and a 
wild-type (WT) control underwent SpeI digestion, generating products of ~8.3kb (wild-type (W) 
allele) and ~9.6kb (mutant (m) allele).  The probe for detection spanned Umod exon 6. (B) 
Genotyping of mice: the C125R mutation introduced an additional BsoBI site, which was used to 
digest PCR products of part of exon 3, leaving the wild-type (W) 144bp product uncut, and cleaving 
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 the mutant product into 116bp (m) and 38bp (not shown) fragments.  Digests from two each of wild-
type (+/+), heterozygous (+/125R) and homozygous mutant (125R/125R) mice shown. (C) Western 
blot analysis of whole kidney lysates from Umod+/+, Umod+/125R and Umod125R/125R male mice aged 8 
weeks (top) and 6 months (bottom).  Umod+/+ mice had only the mature form (M) of uromodulin (U), 
but Umod+/125R and Umod125R/125R mice had varying amounts of the precursor form (P), and high 
molecular weight uromodulin that may be dimers of the precursor. For technical reasons, in the lower 
panel of C, the same lysates were blotted for uromodulin and tubulin on two different gels. Tubulin 
(T) was used as a control. (D) Representative Western blots of urine from males aged 8 weeks (upper 
blot) 6 months (lower blot), with densitometric analysis.  Umod+/+ and Umod+/125R samples diluted 
1/20, Umod125R/125R samples undiluted.  Densitometric measurements are plotted relative to mean of 
Umod+/+ densities (set to 100%). Umod+/+: black bars; Umod+/125R: grey bars; Umod125R/125R: white 
bars.  Values shown as mean+s.e.m; n=9 for 8 week old females, n=8 for 8 week old males, n=7 for 
6 month old Umod+/+ females, n=8 for 6 month old Umod+/125R and Umod125R/125R females, n=10 for 
6 month old Umod+/+ males, n=12 for 6 month old Umod+/125R males, n=6 for 6 month old 
Umod125R/125R males. *p<0.001, **p<0.00001 vs. Umod+/+ littermates of the same age and sex.  
$p<0.05, $$p<0.00001 vs. 8 week old mice of the same sex and genotype (Student’s unpaired 1-tailed 
t-test).  (E) Immunohistochemical analysis of uromodulin showing apical expression in Umod+/+ 
mice, partial intracellular retention in Umod+/125R mice, and dense intracellular deposits in 
Umod125R/125R mice.  Nuclei counterstained with hematoxylin; scale bar: 25µm.  (F) Co-
immunofluorescent labeling for uromodulin (red) and calnexin (green) showing lack of co-
localization in Umod+/+ kidneys, and partial and almost total co-localization in Umod+/125R and 
Umod125R/125R kidneys, respectively.  Nuclei counterstained with DAPI; scale bar: 25µm. 
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Fig. 2. Fibrosis and inflammation in Umod+/+, Umod+/125R and Umod125R/125R kidneys. (A) 
Masson’s trichrome stain in the corticomedullary region at (i) 8 weeks and (ii) 6 months, and (iii) in 
the cortex at 6 months, showing fibrous material (blue). (B) Co-immunofluorescent labeling for 
uromodulin (green) and the T-cell marker CD3 (red) at (i) 8 weeks and (ii) 6 months.  Nuclei 
counterstained with DAPI. (C) Co-immunofluorescent labeling for uromodulin (green) and the 
macrophage marker F4/80 (red) at (i) 8 weeks and (ii) 6 months.  Nuclei are counterstained with 
DAPI. All scale bars: 50µm. 
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Fig. 3. ER stress in Umod+/+, Umod+/125R and Umod125R/125R kidneys. Immunohistochemical 
staining of serial sections for uromodulin and GRP78 in (A) 8 week old and (B) 6 month old mice, 
showing increased expression of GRP78 specifically in TAL cells expressing mutant uromodulin in 
Umod+/125R and Umod125R/125R kidneys.  Nuclei counterstained with hematoxylin; scale bars: 50µm. 
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Fig. 4. Analysis of unfolded protein response pathways in Umod+/+, Umod+/125R and Umod125R/125R 
kidneys.  Immunohistochemical staining of serial sections for uromodulin, ATF6, ATF4 and spliced 
(active) XBP1 (XBP1S) in (A) 8 week old and (B) 6 month old mice, showing upregulation of ATF4 
and XBP1S specifically in TAL cells expressing mutant uromodulin in Umod+/125R and Umod125R/125R 
kidneys, but no upregulation of ATF6.  Nuclei counterstained with hematoxylin; scale bars: 50µm. 
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Fig. 5. Expression of ER stress and UPR pathway components in isolated Umod+/+ (WT) and 
Umod125R/125R (hom) TALs. (A) qRT-PCR analysis of Grp78, Atf6, spliced (active) Xbp1 (Xbp1S), 
Atf4, Chop, and Umod. Gene expression changes are relative to Gapdh and expressed as a fold change 
over WT expression (mean set to 1). Individual TAL preparations (n=6-11) from 2-4 mice per group 
are represented as single points; mean±s.e.m are displayed to the right of each data set; **p<0.01, 
***p<0.001 vs. WT, using 2-tailed Mann-Whitney U test.  (B) Representative Western blots and (C) 
quantification of GRP78, ATF6, XBP1S, and ATF4. Protein was normalized for loading using -
actin and quantification is expressed as a fold change over WT expression (mean set to 1). Individual 
TAL preparations (n=8-11) from 3-4 mice per group are represented as single points; mean±s.e.m are 
displayed to the right of each data set; *p<0.05, **p<0.01, ***p<0.001 vs. WT, using 2-tailed Mann-
Whitney U test. 
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Fig. 6. Analysis of CHOP expression and apoptosis in Umod+/+, Umod+/125R and Umod125R/125R 
kidneys.  Immunohistochemical staining for uromodulin and CHOP, and co-immunofluorescence 
using TUNEL assay to label apoptotic cells (green) and anti-uromodulin antibody to label TAL cells 
(red), in serial sections in (A) 8 week old and (B) 6 month old mice. CHOP is upregulated in the 
nuclei of TAL cells expressing mutant uromodulin in Umod+/125R and Umod125R/125R kidneys, but there 
is an absence of apoptosis in TAL cells.  Nuclei counterstained with hematoxylin 
(immunohistochemistry) or DAPI (immunofluorescence); scale bars: 50µm. 
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 Tables 
 
Table 1. Plasma biochemistry in 8 week and 6 month old mice 
  
Umod+/+ 
Male 
Umod+/125R 
 
Umod125R/125R 
  
Umod+/+ 
Female 
Umod+/125R 
 
Umod125R/125R 
 8 weeks (8) (8) (8)  (9) (9) (9) 
Body weight, g 25.8±0.3 26.1±0.4 26.5±0.6  19.8±0.2 20.7±0.5 20.1±0.8 
Urea, mmol/l 11.5±0.6 11.9±0.6 19.1±1.8$  10.9±1.0 10.7±0.7 20.7±3.1** 
Creatinine, µmol/l 15.5±0.9 16.6±0.4 17.2±1.0  17.0±0.9 15.6±0.9 18.7±2.3 
Pi, mmol/l 3.4±0.1 3.4±0.2 3.3±0.2  3.2±0.2 3.6±0.2 3.4±0.2 
ALP, U/l 150.9±9.5 143.3±5.7 146.8±8.7  170.2±6.9 168.4±8.4 191.0±16.9 
Corr.Ca, mmol/l 2.85±0.03 2.83±0.03 2.77±0.05  2.71±0.03 2.68±0.03 2.77±0.04 
Uric acid, µmol/l 261.1±14.0 262.4±16.8 236.1±34.8  216.9±18.7 225.7±20.7 216.3±19.5 
Osm, mOsm/Kg 345.9±3.6 347.1±2.6 353.6±1.7  351.7±2.8 350.0±2.5 356.3±4.3 
 6 months (10) (12) (6)  (7) (8) (8) 
Body weight, g 32.6±0.9 32.4±0.6 32.9±1.1  27.6±1.0 27.7±1.5 27.0±0.9 
Urea, mmol/l 13.9±0.7 21.5±1.4$$†† 36.4±2.6$$††  9.8±0.6 13.3±1.1**† 20.7±1.0$$ 
Creatinine, µmol/l 17.6±0.9 25.9±4.4* 31.3±4.1$†  19.2±1.6 19.0±1.3† 23.7±1.2*† 
Pi, mmol/l 2.5±0.1 2.8±0.1 2.9±0.2  2.7±0.2 3.1±0.3 2.6±0.1 
ALP, U/l 64.5±3.1 73.0±4.0 98.7±8.0$  90.4±4.8 97.4±7.2 154.8±19.2** 
Corr.Ca2+, mmol/l 2.64±0.02 2.74±0.04* 2.82±0.06**  2.60±0.05 2.72±0.05 2.83±0.03** 
Uric acid, µmol/l 164.1±9.0 181.3±18.3 140.8±11.0  193.6±29.9 207.5±11.5 185.9±25.0 
Osm, mOsm/Kg 353.4±2.9 362.2±2.7* 369.3±2.9**  345.7±1.9 354.9±5.3 356.3±2.3** 
Values are mean±s.e.m; +/+ - wild-types, +/125R - heterozygotes, 125R/125R - homozygotes; 
numbers in parentheses denote number of mice.  ALP = alkaline phosphatase; Corr.Ca = calcium 
corrected for albumin; Osm = osmolality.  *p<0.05; **p<0.01; $p<0.001; $$p<0.0001 compared to 
wild-type mice of the same age and sex.  †p<0.05; ††p<0.0001 compared to 8 week old mice of the 
same sex and genotype.   
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 Table 2. Urinary parameters in 8 week and 6 month old mice 
  
Umod+/+ 
Male 
Umod+/125R 
 
Umod125R/125R 
   
Umod+/+ 
Female 
Umod+/125R 
 
Umod125R/125R 
 8 weeks (8) (8) (8)  (9) (9) (9) 
24hr vol/bw, µl/g 99.5±5.0 102.3±10.7 173.1±7.1$  66.7±7.7 66.8±7.1 143.5±10.1$ 
Osm, mOsm/Kg 2212±64 1960±78* 1322±90$  2097±115 2330±84 1642±139* 
Cr clear, ml/min 0.43±0.03 0.40±0.02 0.40±0.03  0.24±0.03 0.29±0.04 0.28±0.04 
FEUA, % 0.74±0.02 0.70±0.07 0.60±0.11  1.56±0.41 1.16±0.17 1.00±0.17 
24hr UA, nmol 1165±70 1051±82 710±94**  910±84 988±139 802±111 
24hr Ca, µmol 3.47±0.30 4.12±0.47 4.46±0.58  1.99±0.24 3.26±0.64* 3.49±0.42** 
pH 6.67±0.07 6.53±0.13 6.27±0.06**  6.48±0.08 6.31±0.08 5.94±0.05$ 
 6 months (10) (12) (6)  (7) (8) (8) 
24hr vol/bw, µl/g 76.3±7.6 98.8±6.7* 170.1±21.0$  52.4±8.3 100.9±38.2 215.3±18.3$ 
Osm, mOsm/Kg 1581±118 1198±75* 657±42$  2153±212 1653±182* 663±25$ 
Cr clear, ml/min 0.31±0.04 0.25±0.04 0.16±0.06*  0.24±0.03 0.24±0.03 0.19±0.02 
FEUA, % 1.52±0.08 0.77±0.17** a0.54±0.20**  1.54±0.33 0.75±0.04* 0.46±0.13** 
24hr UA, nmol 1024±140 426±47** a213±67**  819±80 526±65* 197±39$ 
24hr Ca, µmol 2.92±0.40 4.52±0.25** 4.28±0.80*  2.08±0.32 3.48±0.31** 4.65±0.24$ 
pH 6.51±0.08 5.71±0.07$ 5.79±0.09$  6.50±0.13 5.90±0.10** 5.60±0.07$ 
Values are mean±s.e.m; +/+ - wild-types, +/125R - heterozygotes, 125R/125R - homozygotes; 
numbers in parentheses denote number of mice.  24hr vol/bw = 24 hour urine volume (vol) corrected 
for body weight (bw); Osm = osmolality; Cr clear = creatinine clearance; FEUA = fractional excretion 
of uric acid; 24hr UA = 24 hour uric acid excretion; 24hr Ca = 24 hour calcium excretion.  an=4 
because two of the urine samples were below the lower limit of detection for uric acid concentration.  
*p<0.05; **p<0.005; $p<0.0001 compared to wild-type mice of the same age and sex. 
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 ABBREVIATIONS 
ADTKD: autosomal dominant tubulointerstitial kidney disease; ALP: alkaline phosphatase; ATF6: 
activating transcription factor-6 alpha; BiP: binding immunoglobulin protein; cb: calcium binding; 
CHOP: CCAAT/enhancer-binding protein homologous protein; D8C: domain of 8 cysteines; DAB: 
3,3’-Diaminobenzidine; DAPI: 4',6-diamidino-2-phenylindole; ER: endoplasmic reticulum; ERAD: 
ER-associated degradation; EGF: epidermal growth factor-like; ES: embryonic stem; ESRF: end-
stage renal failure; FEUA: fractional excretion of uric acid; FJHN1: familial juvenile hyperuricemic 
nephropathy type 1; GCKD: glomerulocystic kidney disease; GPI: glycosylphosphatidylinositol; 
GRP78: glucose-regulated protein 78; HEK: human embryonic kidney; HRP: horseradish peroxidase; 
IRE1: inositol-requiring enzyme-1; MCKD2: medullary cystic kidney disease type 2; NKCC2: 
Na+:K+:2Cl- co-transporter; PERK: RNA-activated protein kinase-like ER kinase ROMK: renal outer 
medullary potassium channel; RT: reverse transcriptase; SEM: standard error of the mean; SP: signal 
peptide; TAL: thick ascending limb; TM: transmembrane; TUNEL: terminal deoxynucleotidyl 
transferase dUTP nick end labelling; UMOD: uromodulin gene; UPR: unfolded protein response; 
WT: wild-type; ZP: zona pellucida. 
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Supplementary Table 1. Comparison of uromodulin mutant mouse models 
Study/Reference (Bernascone et 
al., 2010) 
(Takiue et al., 
2008a; Takiue et 
al., 2008b) 
(Kemter et al., 
2009;Kemter et 
al., 2013) 
(Kemter et 
al., 2013) 
Piret et al 
(Current 
study) 
Derivation Transgenic Transgenic ENU ENU HR 
Background strain FVB C57/Bl6 C3HeB/FeJ C3HeB/FeJ C57/Bl6 
Mutation Human C148W Human C148W A227T C93F C125R 
Genotype [overexpression] [overexpression] Het & hom Het & hom Het & hom 
Clinical features 
 Renal failure 
 
✓ 
 
X 
 
✓ 
 
✓ e 
 
✓ 
 Plasma uric acid – NR  a NR – 
 Plasma calcium NR NR  b  e  
 Plasma ALP NR NR  b  e  c 
 Plasma osmolality  NR NR NR  
 Urine concentrating 
 defect 
 
✓ 
 
NR 
 
✓ 
 
✓ e 
 
✓ 
 Urinary UA excretion NR NR   e  
 Urinary pH  NR NR NR  
 Urinary calcium  NR   e  
 Urinary uromodulin 
 excretion 
 
 
 (human protein 
only) 
 
 
 
 
 
 
Histological features 
 Fibrosis 
 
✓ 
 
X 
 
✓ c 
 
✓ 
 
✓ 
 Glomerulosclerosis X NR X d NR ✓ c 
 Immune infiltration ✓ NR ✓ c ✓ ✓ 
 Tubular 
 dilation/cysts 
 
✓ 
NR  
X d 
 
✓ e 
 
X 
 Uromodulin ER 
 retention 
 
✓ 
 
NR 
 
✓ d 
 
✓ e 
 
✓ 
 ER stress NR NR NR NR ✓ 
 Apoptosis X NR NR NR ✓ 
ENU: N-ethyl-N-nitrosourea; HR: homologous recombination; het: heterozygotes; hom: 
homozygotes; ALP: alkaline phosphatase; UA: uric acid; ER: endoplasmic reticulum; ✓: present; 
X: absent; : increased; : decreased; –: not altered; NR: not reported; a this mouse mutation 
corresponds to the human mutation C126R found in ADTKD-UMOD patients; ahomozygous 
females only; bhomozygous males only; chomozygotes only; donly homozygotes studied; eonly 
heterozygotes studied. 
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